Novo Nordisk issues statement on ‘inauthentic’ Hims & Hers semaglutide pill

Novo Nordisk (NVO) issued the following statement regarding the announcement by Hims & Hers (HIMS) that they will mass-market an “unapproved, inauthentic, and untested knockoff” semaglutide pill. “The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety. Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. This is another example of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 products, and the FDA has previously warned them about their deceptive advertising of GLP-1 knock-offs.